{
    "response": "**Overall Treatment Decision:** Yes\n\n**Specific Treatment Recommendations:**\n\n*   **Treatment:** Intravenous Methylprednisolone\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** To reduce acute inflammation To accelerate recovery of visual function and coordination Standard of care for acute demyelinating relapse\n\n*   **Treatment:** Gastroprotection (e.g., Proton Pump Inhibitor)\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** To prevent gastritis/ulceration associated with high-dose steroids\n\n*   **Treatment:** Disease Modifying Therapy (e.g., Ocrelizumab, Natalizumab)\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Must confirm specific diagnosis (MS vs NMO vs MOG) first as treatments differ Requires screening for latent infections prior to initiation\n\n*   **Treatment:** Physiotherapy\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** To address gait ataxia and fall risk To assist with coordination rehabilitation\n\n\ntreatments = [{\"treatment\": \"Intravenous Methylprednisolone\", \"timing\": \"Start Now\", \"reasons\": [\"To reduce acute inflammation\", \"To accelerate recovery of visual function and coordination\", \"Standard of care for acute demyelinating relapse\"]}, {\"treatment\": \"Gastroprotection (e.g., Proton Pump Inhibitor)\", \"timing\": \"Start Now\", \"reasons\": [\"To prevent gastritis/ulceration associated with high-dose steroids\"]}, {\"treatment\": \"Disease Modifying Therapy (e.g., Ocrelizumab, Natalizumab)\", \"timing\": \"Delay\", \"reasons\": [\"Must confirm specific diagnosis (MS vs NMO vs MOG) first as treatments differ\", \"Requires screening for latent infections prior to initiation\"]}, {\"treatment\": \"Physiotherapy\", \"timing\": \"Start Now\", \"reasons\": [\"To address gait ataxia and fall risk\", \"To assist with coordination rehabilitation\"]}]"
}